Keywords: USA, FDA, Sanofi Pasteur, Fluzone, Bayer, Regorafenib, Influenza, Stromal tumors, GIST

US FDA licenses Sanofi Pasteur's Fluzone Intradermal; fast-tracks Bayer’s regorafenib

Article | 11 May 2011

Print This

Sanofi Pasteur, the vaccines division of French drug major Sanofi (Euronext: SAN), says that the US Food and Drug Administration ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in